HP Inc., a leading player in microfluidics technologies, announced the U.S. launch of its new D100 Single Cell Dispenser. Using HP’s proven approach to inkjet-based microfluidics, the D100 Single Cell Dispenser democratizes single-cell analysis with high occupancy, viability, and precision, facilitating the acceleration of discovery of therapeutics and helping advance life science and pharma research around the world.
“As an inkjet leader, HP has decades of experience in microfluidics,“ said Philippe Lesage, VP and GM, Specialty Printing & Technology Solutions at HP. “This provides us with the foundation to handle various types of fluids at a micro-level beyond our well-known HP inks and extend into new and exciting domains, including dispensing and cell isolation for drug discovery research, product coding and marking, and late-stage packaging. Applying our expertise and scalability in these areas is a key driver of innovation for the business. While leading pharma companies and research institutions around the world are already using our microfluidics technology for dose response studies, we are excited to bring this new single cell isolation solution to market, and we expect this will accelerate the transformation of the industry’s approach to drug and vaccine research and development.”
HP’s simple but powerful software combines cell isolation and reagent dispense for workflow miniaturization. Researchers can dispense single cells, as well as precisely dispense picoliter through microliter volumes of reagents in an easy-to-navigate user interface with real time reporting built in.
